These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

567 related articles for article (PubMed ID: 7511016)

  • 1. G-CSF primed peripheral blood progenitor cells in autologous bone marrow transplantation: parameters affecting bone marrow engraftment.
    Bolwell BJ; Fishleder A; Andresen SW; Lichtin AE; Koo A; Yanssens T; Burwell R; Baucco P; Green R
    Bone Marrow Transplant; 1993 Dec; 12(6):609-14. PubMed ID: 7511016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of G-CSF with GM-CSF for mobilizing peripheral blood progenitor cells and for enhancing marrow recovery after autologous bone marrow transplant.
    Bolwell BJ; Goormastic M; Yanssens T; Dannley R; Baucco P; Fishleder A
    Bone Marrow Transplant; 1994 Dec; 14(6):913-8. PubMed ID: 7536072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
    Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
    Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience.
    Olivieri A; Offidani M; Montanari M; Ciniero L; Cantori I; Ombrosi L; Masia CM; Centurioni R; Mancini S; Brunori M; Leoni P
    Haematologica; 1998 Apr; 83(4):329-37. PubMed ID: 9592983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of autologous filgrastim (G-CSF)-mobilized peripheral blood progenitor cells to restore hemopoiesis after high-dose chemotherapy for lymphoid malignancies.
    Sheridan WP; Begley CG; To LB; Grigg A; Szer J; Maher D; Green MD; Rowlings PA; McGrath KM; Cebon J
    Bone Marrow Transplant; 1994 Jul; 14(1):105-11. PubMed ID: 7524904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokine-primed bone marrow stem cells vs. peripheral blood stem cells for autologous transplantation: a randomized comparison of GM-CSF vs. G-CSF.
    Weisdorf D; Miller J; Verfaillie C; Burns L; Wagner J; Blazar B; Davies S; Miller W; Hannan P; Steinbuch M; Ramsay N; McGlave P
    Biol Blood Marrow Transplant; 1997 Oct; 3(4):217-23. PubMed ID: 9360784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engraftment with peripheral blood stem cells using noncontrolled-rate cryopreservation: comparison with autologous bone marrow transplantation.
    Rosenfeld CS; Gremba C; Shadduck RK; Zeigler ZR; Nemunaitis J
    Exp Hematol; 1994 Mar; 22(3):290-4. PubMed ID: 7509292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma.
    Moskowitz CH; Glassman JR; Wuest D; Maslak P; Reich L; Gucciardo A; Coady-Lyons N; Zelenetz AD; Nimer SD
    Clin Cancer Res; 1998 Feb; 4(2):311-6. PubMed ID: 9516916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF.
    Hohaus S; Goldschmidt H; Ehrhardt R; Haas R
    Exp Hematol; 1993 Apr; 21(4):508-14. PubMed ID: 7681782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis.
    Kanteti R; Miller K; McCann J; Roitman D; Morelli J; Hurley C; Berkman E; Schenkein D
    Bone Marrow Transplant; 1999 Sep; 24(5):473-81. PubMed ID: 10482930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. G-CSF post-autologous progenitor cell transplantation: a randomized study of 5, 10, and 16 micrograms/kg/day.
    Bolwell B; Goormastic M; Dannley R; Andresen S; Overmoyer B; Mendez Z; Kalaycioglu M; DeMars D; Wise K; Pohlman B
    Bone Marrow Transplant; 1997 Feb; 19(3):215-9. PubMed ID: 9028548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delayed G-CSF after autologous progenitor cell transplantation: a prospective randomized trial.
    Bolwell BJ; Pohlman B; Andresen S; Kalaycio M; Goormastic M; Wise K; Wakeling A; Dannley R; Overmoyer B
    Bone Marrow Transplant; 1998 Feb; 21(4):369-73. PubMed ID: 9509971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of G-CSF-primed peripheral blood progenitor cells and bone marrow auto transplantation: clinical assessment and cost-effectiveness.
    Faucher C; le Corroller AG; Blaise D; Novakovitch G; Manonni P; Moatti JP; Maraninchi D
    Bone Marrow Transplant; 1994 Dec; 14(6):895-901. PubMed ID: 7536070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma.
    Aurlien E; Holte H; Pharo A; Kvaløy S; Jakobsen E; Smeland EB; Kvalheim G
    Bone Marrow Transplant; 1998 May; 21(9):873-8. PubMed ID: 9613778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utilization of recombinant human GM-CSF to enhance peripheral progenitor cell yield for autologous transplantation.
    Ho AD; Haas R; Korbling M; Dietz M; Hunstein W
    Bone Marrow Transplant; 1991; 7 Suppl 1():13-7. PubMed ID: 1675138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors affecting the mobilization of primitive and committed hematopoietic progenitors into the peripheral blood of cancer patients.
    Schneider JG; Crown JP; Wasserheit C; Kritz A; Wong G; Reich L; Norton L; Moore MA
    Bone Marrow Transplant; 1994 Dec; 14(6):877-84. PubMed ID: 7536069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet transfusion requirements during autologous peripheral blood progenitor cell transplantation correlate with the pretransplant platelet count.
    Bolwell BJ; Goormastic M; Andresen S; Overmoyer B; Pohlman B; Kalaycio M
    Bone Marrow Transplant; 1997 Sep; 20(6):459-63. PubMed ID: 9313878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased yield of myeloid progenitor cells in bone marrow harvested for autologous transplantation by pretreatment with recombinant human granulocyte-colony stimulating factor.
    Johnsen HE; Hansen PB; Plesner T; Jensen L; Gaarsdal E; Andersen H; Hansen SW; Birgens H; Jacobsen GK; Kjaersgaard E
    Bone Marrow Transplant; 1992 Sep; 10(3):229-34. PubMed ID: 1384899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship of CD34+ cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation.
    Kiss JE; Rybka WB; Winkelstein A; deMagalhaes-Silverman M; Lister J; D'Andrea P; Ball ED
    Bone Marrow Transplant; 1997 Feb; 19(4):303-10. PubMed ID: 9051238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of autografting using mobilized peripheral blood stem cells with and without granulocyte colony-stimulating factor in malignant lymphomas.
    Brice P; Divine M; Marolleau JP; Haioun C; Dalcortivo L; Sitthy X; Beaujean F; Norol F; Benbunan M; Reyes F
    Bone Marrow Transplant; 1994 Jul; 14(1):51-5. PubMed ID: 7524907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.